title: Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors.
abstract: Before the advent of the human epidermal growth factor receptor 2 (HER2)-targeted monoclonal antibody trastuzumab, HER2-positive breast cancers were difficult to treat and had a poor prognosis. Adjuvant trastuzumab is now an important part of the treatment regimen for many women with HER2-positive breast cancer and has undoubtedly resulted in a significant improvement in prognosis, but it is associated with a risk for cardiotoxicity. In this review, we describe the prevalence, patient characteristics, and risk factors for cardiotoxicity associated with use of adjuvant trastuzumab. Understanding risk factors for trastuzumab-induced cardiotoxicity and appropriate patient monitoring during trastuzumab treatment allows for safe and effective use of this important adjuvant therapy.
authors.affiliation: Department of Hematology/Oncology, Marshfield Clinic Weston Center, 3501 Cranberry Boulevard, Weston, WI 54476, USA.
authors.forename: Adedayo A
authors.initials: AA
authors.lastname: Onitilo
authors.affiliation: Marshfield Clinic Cancer Care at St. Michaels, Stevens Point, WI, USA.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Engel
authors.affiliation: Office of Scientific Writing, Marshfield Clinic Research Foundation, Marshfield, WI, USA.
authors.forename: Rachel V
authors.initials: RV
authors.lastname: Stankowski
keywords: breast cancer; doxorubicin; epidermal growth factor; heart failure; oxidative stress; trastuzumab
references.citation: Exp Clin Cardiol. 2011 Fall;16(3):70-4
references.pmid: 22065936
references.citation: Maturitas. 2010 Apr;65(4):308-14
references.pmid: 20138719
references.citation: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243
references.pmid: 22513938
references.citation: Breast. 2003 Apr;12(2):92-8
references.pmid: 14659337
references.citation: Jpn J Clin Oncol. 2011 May;41(5):709-12
references.pmid: 21355003
references.citation: Stem Cells Transl Med. 2012 Apr;1(4):289-97
references.pmid: 23197808
references.citation: Lancet. 2010 Jan 30;375(9712):377-84
references.pmid: 20113825
references.citation: Acta Oncol. 2014 Feb;53(2):186-94
references.pmid: 23957715
references.citation: J Clin Oncol. 2010 Sep 1;28(25):3910-6
references.pmid: 20679614
references.citation: J Am Soc Echocardiogr. 2012 Nov;25(11):1141-52
references.pmid: 23000452
references.citation: JAMA. 2006 Nov 1;296(17):2105-11
references.pmid: 17077375
references.citation: Cancer. 2012 Apr 15;118(8 Suppl):2207-16
references.pmid: 22488695
references.citation: Breast Cancer Res Treat. 2011 Dec;130(3):845-54
references.pmid: 21918836
references.citation: Circ Res. 2010 Jan 8;106(1):35-46
references.pmid: 20056944
references.citation: J Clin Oncol. 2004 Mar 15;22(6):1063-70
references.pmid: 15020607
references.citation: Ann Oncol. 2007 Aug;18(8):1335-41
references.pmid: 17693647
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references.pmid: 15738535
references.citation: Expert Opin Drug Saf. 2010 Mar;9(2):335-46
references.pmid: 20175700
references.citation: Ann Oncol. 2012 Apr;23(4):897-902
references.pmid: 21828361
references.citation: Curr Med Res Opin. 2013 Aug;29(8):1015-24
references.pmid: 23692263
references.citation: J Card Fail. 2012 Feb;18(2):113-9
references.pmid: 22300778
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7811-9
references.pmid: 16258083
references.citation: Eur J Heart Fail. 2012 Feb;14(2):130-7
references.pmid: 22219501
references.citation: Lancet Oncol. 2012 Sep;13(9):869-78
references.pmid: 22884505
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3525-33
references.pmid: 17687157
references.citation: Lancet Oncol. 2011 Mar;12(3):236-44
references.pmid: 21354370
references.citation: Target Oncol. 2014 Jun;9(2):111-22
references.pmid: 23852665
references.citation: Drug Saf. 2008;31(6):459-67
references.pmid: 18484781
references.citation: Clin J Oncol Nurs. 2011 Feb;15(1):63-71
references.pmid: 21278042
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6129-34
references.pmid: 19917839
references.citation: Intern Emerg Med. 2012 Oct;7(5):439-46
references.pmid: 22714882
references.citation: Ann Oncol. 2010 Nov;21(11):2153-2160
references.pmid: 20351072
references.citation: J Physiol Biochem. 2012 Dec;68(4):701-11
references.pmid: 22351038
references.citation: Appetite. 2008 Jan;50(1):50-6
references.pmid: 17602789
references.citation: Cancer Control. 2013 Jan;20(1):32-42
references.pmid: 23302905
references.citation: Breast. 2007 Jun;16(3):323-5
references.pmid: 17292609
references.citation: Med Care. 2014 May;52(5):e30-8
references.pmid: 22643199
references.citation: Cardiology. 2012;123(4):240-7
references.pmid: 23207160
references.citation: Curr Pharm Des. 2014;20(30):4879-98
references.pmid: 24283956
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: Arzneimittelforschung. 2012 Sep;62(9):401-9
references.pmid: 22918857
references.citation: Ann Oncol. 2013 Sep;24(9):2278-84
references.pmid: 23704196
references.citation: Eur J Cancer. 2013 Sep;49(13):2900-9
references.pmid: 23706982
references.citation: J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305
references.pmid: 22949432
references.citation: BMC Cancer. 2007 Aug 08;7:153
references.pmid: 17686164
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7820-6
references.pmid: 16258084
references.citation: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references.pmid: 22700443
references.citation: J Hematol Oncol. 2013 Jun 03;6:38
references.pmid: 23731980
references.citation: J Natl Compr Canc Netw. 2011 Feb;9(2):243-9
references.pmid: 21310845
references.citation: J Clin Oncol. 2010 Jul 20;28(21):3422-8
references.pmid: 20530280
references.citation: J Gynecol Obstet Biol Reprod (Paris). 2011 Apr;40(2):144-8
references.pmid: 21227599
references.citation: N Engl J Med. 2006 Feb 23;354(8):809-20
references.pmid: 16495393
references.citation: Anticancer Res. 2013 Apr;33(4):1717-20
references.pmid: 23564821
references.citation: Heart. 2013 May;99(9):634-9
references.pmid: 23349345
references.citation: Pharmacogenomics. 2013 Jan;14(2):205-13
references.pmid: 23327580
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1215-21
references.pmid: 11870163
references.citation: Anticancer Res. 2013 Jun;33(6):2569-76
references.pmid: 23749910
references.citation: Curr Oncol. 2010 Aug;17(4):20-33
references.pmid: 20697511
references.citation: Cancer Epidemiol. 2009 Nov;33(5):315-8
references.pmid: 19896917
references.citation: J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S26-9
references.pmid: 16958666
references.citation: Cardiol Res Pract. 2012;2012:135819
references.pmid: 23050193
references.citation: Arch Med Sci. 2012 May 9;8(2):227-35
references.pmid: 22661994
references.citation: Cancer Causes Control. 2012 Jul;23(7):991-1008
references.pmid: 22527174
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references.pmid: 18250349
references.citation: N Engl J Med. 2005 Oct 27;353(17):1784-92
references.pmid: 16251534
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: Breast Cancer Res Treat. 2012 Jul;134(1):291-8
references.pmid: 22476854
references.citation: Circ Heart Fail. 2013 May;6(3):420-6
references.pmid: 23425978